【摘要】 目的探讨阿立哌唑对儿童期首发精神分裂症的临床疗效和安全性。方法对60例年龄<14岁首次发病患儿用阿立哌唑治疗8周,以阳性和阴性症状量表(PANSS)评定临床疗效。以不良反应量表(TESS)和实验室监测评价安全性,于基线时,实验第1、2、4、6、8周末分别评定各量表。统计方法为描述性分析和配对t检验。结果共收集有效病例60例,其中基本痊愈占20.0%(12/60),显著进步占30.0%(18/60),好转占30.0%(18/60)和无效占20.0%(12/60)。PANSS总分及各分量表分治疗前后比较均差异有统计学意义(P<0.01),阿立哌唑对阳性、阴性症状以及一般精神病性症状均有良好疗效。无严重不良反应。结论阿立哌唑能缓解儿童期首发精神分裂症的精神病性症状,疗效好,安全性高。更多还原

【Abstract】 Objective The aim of this study was to evaluate the efficacy and safety of aripirazole in the treatment of childhood patients with first-episode schizophrehia.Methods 60 patients with first-episode schizophrenia(age<14)were included in this 8 week open clinical study.The positive and negative symptom scale(PANSS)was used to evaluate the severity and the improvement of mental symptoms,The Treatment Emergent side Effect scale(TESS)and laboratory tests were used to assess the adverse effects.Scales were evaluated at baseline and the end of weeks1、2、4、6,8.Descriptive analsysis and paired t-test were performed in statistical analysis.Results 60 valid cases were collected,among the 60 patients,20.0%met the criteria of complete relief,30.0%significantly improved,30.0%improved,and 20.0%got no change.significant differences existed in total PANSS scores and factor scores of PANSS after 8 week treatment of aripirazole,Aripirazole showed good effect on the positive,negative as well as general psychopathological symptoms of childhood patients with first-episode schizophrenia.No serious adverse events were found during the treatment.Conclusion This study suggests that aripirazole is an effective and safe antipsychotic in the treatment of childhood patients with first-episode schizophrenia.更多还原